Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547204 | 1.00 | CA2 (0.32) | CA2 | |
| SCHEMBL3455764 | 0.88 | — | — | |
| SCHEMBL14834118 | 0.85 | CA2 (0.36) | CA2 | |
| SCHEMBL31682148 | 0.84 | CA2 (0.32) | CA2 | |
| SCHEMBL17231287 | 0.83 | — | — | |
| SCHEMBL19506977 | 0.83 | — | — | |
| SCHEMBL18022040 | 0.83 | CA2 (0.35) | CA2 | |
| SCHEMBL16692396 | 0.83 | CA2 (0.31) | CA2 | |
| SCHEMBL11834983 | 0.81 | CA2 (0.35) | CA2 | |
| SCHEMBL19385898 | 0.80 | LMNA (0.35) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346738-B2 | Process for the preparation of treprostinil and derivatives thereof | SCIPHARM SARL (LU) | 2016-05-24 | — | — | US | disclosed |
| US-20150126761-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | SCIPHARM SARL (LU) | 2015-05-07 | — | — | US | disclosed |
| EP-2861554-A2 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | SciPharm SàRL (LU) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013174848-A2 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | SCIPHARM SÀRL (LU) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126761-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF | TREH, TPP1, TPP2 | CA2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.